Quantifying Residual DNA in Biotherapeutic Manufacturing
Biotherapeutics must go through rigorous purification processes during their development and manufacturing. However, low levels of residual or plasmid DNA can often remain after purification, affecting the safety and efficacy of final products.
Although many labs opt for in-house methods to screen for residual DNA, these can be costly, time-consuming and require specialist expertise.
Discover a fully integrated commercial real-time qPCR solution that can improve efficiency, reduce workloads and ensure regulatory compliance in your lab today.
Download this application focus to explore:
• How to produce reliable, reproducible results for in-process and lot-release studies
• An optimized, rapid sample preparation protocol
• An established and trusted system adopted for use by major biopharma companies